PerkinElmer is pleased to announce that today it completed the acquisition of Caliper Life Sciences, an exciting milestone in PerkinElmer’s evolution. The purchase, announced in September.
Bringing Caliper into PerkinElmer will significantly strengthen leadership position in the growing area of personalized medicine, providing pharmaceutical companies and clinicians with the tools and knowledge they need to enable individualized diagnoses and treatments. PKI’s work moving ahead in this emerging field will be made possible by an outstanding team of people from Caliper and PerkinElmer collaborating together to leverage the combined power of their knowledge and expertise to deliver insight-driven innovations.
Bio-discovery and Caliper will combine to form PerkinElmer’s new Life Sciences & Technology (LST) Strategic Business Element (SBE). In a statement today, Robert Friel, chairman and CEO of PerkinElmer, said that he is confident that joining together these two organizations will create powerful momentum and inspire new ways to develop targeted solutions to meet customer needs across the in vitro to in vivo value chain, from disease research to drug discovery to clinical applications. It will also enable PKI to expand its offerings across our biomedical, diagnostics, environmental and food safety end markets.